AI Engines For more Details: Perplexity Kagi Labs You
Skin Disorders: Clobetasol propionate is commonly prescribed for the treatment of various inflammatory skin conditions, including eczema (atopic dermatitis), psoriasis, allergic dermatitis, contact dermatitis, seborrheic dermatitis, and lichen planus. It helps to reduce inflammation, itching, redness, and swelling associated with these skin disorders by suppressing the immune response and inhibiting the release of inflammatory mediators.
Scalp Conditions: Clobetasol propionate is also available in a foam or shampoo formulation for the treatment of scalp conditions such as scalp psoriasis, seborrheic dermatitis of the scalp, and scalp eczema. These formulations are specifically designed for application to the scalp and can help alleviate symptoms such as itching, scaling, and inflammation.
Topical Steroid Therapy: Clobetasol propionate is classified as a high-potency topical corticosteroid, which means it is more potent and has a greater anti-inflammatory effect compared to lower-potency corticosteroids. It is typically used for short-term treatment of acute flare-ups or severe symptoms, as prolonged use of potent corticosteroids may increase the risk of side effects such as skin thinning, stretch marks, and telangiectasia (dilated blood vessels).
Psoriasis: Clobetasol propionate may be particularly effective in the treatment of psoriasis, a chronic autoimmune skin disorder characterized by red, scaly patches of skin. It helps to reduce inflammation and scaling associated with psoriatic lesions, alleviate itching and discomfort, and promote the clearance of psoriatic plaques. Clobetasol propionate may be used alone or in combination with other topical or systemic medications for the management of psoriasis.
Eczema: Clobetasol propionate is also effective in the treatment of eczema, a chronic inflammatory skin condition characterized by dry, itchy, and inflamed patches of skin. Topical application of clobetasol propionate helps to relieve itching and inflammation, moisturize the skin, and improve skin barrier function, thereby reducing the frequency and severity of eczema flares and promoting symptom relief.
Safety and Side Effects: Clobetasol propionate is generally well-tolerated when used as directed, but side effects may occur, especially with prolonged or excessive use. Common side effects may include skin irritation, burning, stinging, itching, dryness, or peeling at the site of application. Less common side effects may include skin thinning, skin discoloration, allergic contact dermatitis, and systemic absorption leading to adrenal suppression or Cushing's syndrome.
Precautions: Clobetasol propionate should be used with caution in certain populations, including children, pregnant or breastfeeding women, and individuals with a history of hypersensitivity reactions to corticosteroids. It should not be applied to open wounds, broken or infected skin, or areas of skin affected by viral infections such as herpes or chickenpox. Long-term use of clobetasol propionate should be avoided, and treatment should be discontinued once symptoms have resolved to minimize the risk of side effects.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Dorea | genus | Decreases |
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Phocaeicola | genus | Decreases |
| 0 | 1 | Streptococcus | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Phocaeicola vulgatus | species | Decreases |
| 1 | 0 | Dorea formicigenerans | species | Decreases |
| 1 | 0 | Streptococcus parasanguinis | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.4 | 1.4 | |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 1.6 | 0.5 | 2.2 |
| Allergies | 1.1 | 0.8 | 0.38 |
| Allergy to milk products | 0.3 | 0.7 | -1.33 |
| Alopecia (Hair Loss) | 0.6 | 0.6 | |
| Alzheimer's disease | 1.9 | 1.5 | 0.27 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1 | 1 | |
| Ankylosing spondylitis | 1.6 | 0.3 | 4.33 |
| Anorexia Nervosa | 0.7 | 1.5 | -1.14 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 2.1 | 1.1 | 0.91 |
| Atherosclerosis | 0.7 | 0.6 | 0.17 |
| Atrial fibrillation | 2 | 1.2 | 0.67 |
| Autism | 3.3 | 3.3 | 0 |
| Autoimmune Disease | 0.3 | 0.5 | -0.67 |
| Barrett esophagus cancer | 0.3 | -0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.5 | 0.5 | |
| Bipolar Disorder | 0.7 | 0.5 | 0.4 |
| Brain Trauma | 0.3 | 0.8 | -1.67 |
| Cancer (General) | 0.1 | -0.1 | |
| Carcinoma | 1.6 | 1.3 | 0.23 |
| Celiac Disease | 1.3 | 1.3 | 0 |
| Cerebral Palsy | 0.6 | 0.8 | -0.33 |
| Chronic Fatigue Syndrome | 0.8 | 2.3 | -1.87 |
| Chronic Kidney Disease | 1.3 | 0.5 | 1.6 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.5 | 0.8 | -0.6 |
| Chronic Urticaria (Hives) | 0.3 | 0.9 | -2 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 0.8 | -0.14 |
| Cognitive Function | 1.6 | 0.8 | 1 |
| Colorectal Cancer | 2.8 | 1.1 | 1.55 |
| Constipation | 0.6 | 0.5 | 0.2 |
| Coronary artery disease | 0.3 | 1.2 | -3 |
| COVID-19 | 2.4 | 2.9 | -0.21 |
| Crohn's Disease | 3 | 2.2 | 0.36 |
| Cushing's Syndrome (hypercortisolism) | 0.6 | -0.6 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.4 | 1.1 | -1.75 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 3.3 | 2.8 | 0.18 |
| Dermatomyositis | 0.3 | 0.3 | |
| Eczema | 0.3 | 0.7 | -1.33 |
| Endometriosis | 1.6 | 0.5 | 2.2 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 1 | 1.3 | -0.3 |
| erectile dysfunction | 0.3 | 0.3 | |
| Fibromyalgia | 2.2 | 0.9 | 1.44 |
| Functional constipation / chronic idiopathic constipation | 1.8 | 2.1 | -0.17 |
| gallstone disease (gsd) | 1.4 | 0.5 | 1.8 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.7 | 0.3 | 1.33 |
| Generalized anxiety disorder | 0.6 | 0.6 | 0 |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 0.6 | 0.6 | |
| Graves' disease | 0.7 | 1.7 | -1.43 |
| Gulf War Syndrome | 0.3 | 0.4 | -0.33 |
| Halitosis | 0.6 | 0.3 | 1 |
| Hashimoto's thyroiditis | 1.8 | 0.3 | 5 |
| Heart Failure | 1 | 0.5 | 1 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.5 | |
| hyperglycemia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 2.2 | 1.5 | 0.47 |
| Hypoxia | 1.3 | 1.3 | |
| IgA nephropathy (IgAN) | 1 | 1.2 | -0.2 |
| Inflammatory Bowel Disease | 1.7 | 2 | -0.18 |
| Insomnia | 1.2 | 1.1 | 0.09 |
| Intelligence | 0.5 | 0.5 | 0 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 2.1 | 2.1 | 0 |
| ischemic stroke | 1 | 0.8 | 0.25 |
| Liver Cirrhosis | 2.5 | 1.7 | 0.47 |
| Long COVID | 1.3 | 1.8 | -0.38 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.6 | -0.6 | |
| Mast Cell Issues / mastitis | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | 0.5 | -0.67 |
| ME/CFS without IBS | 0.3 | 1.1 | -2.67 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 0.3 | 0.5 | -0.67 |
| Metabolic Syndrome | 2.5 | 3 | -0.2 |
| Mood Disorders | 2.4 | 2.2 | 0.09 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.8 | 2.7 | -0.5 |
| Multiple system atrophy (MSA) | 0.2 | 0.2 | |
| myasthenia gravis | 0.3 | 0.5 | -0.67 |
| neuropathic pain | 1.3 | -1.3 | |
| Neuropathy (all types) | 0.3 | 1 | -2.33 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.2 | 0.8 | 1.75 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 2.8 | 2.6 | 0.08 |
| obsessive-compulsive disorder | 1.9 | 1.6 | 0.19 |
| Osteoarthritis | 0.8 | 0.6 | 0.33 |
| Osteoporosis | 0.8 | 1.2 | -0.5 |
| pancreatic cancer | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 2 | 2.6 | -0.3 |
| Polycystic ovary syndrome | 2.9 | 1.1 | 1.64 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.9 | 0.5 | 0.8 |
| Primary sclerosing cholangitis | 1.2 | 0.4 | 2 |
| Psoriasis | 0.9 | 1.7 | -0.89 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 2.8 | 1.8 | 0.56 |
| Rosacea | 0.5 | -0.5 | |
| Schizophrenia | 1.2 | 1.3 | -0.08 |
| Sjögren syndrome | 1.2 | 1.5 | -0.25 |
| Sleep Apnea | 0.6 | 0.8 | -0.33 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.6 | |
| Stress / posttraumatic stress disorder | 1.8 | 1.3 | 0.38 |
| Systemic Lupus Erythematosus | 1.4 | 0.5 | 1.8 |
| Tic Disorder | 0.6 | 1 | -0.67 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 1.3 | 1.5 | -0.15 |
| Type 2 Diabetes | 3.1 | 3.1 | 0 |
| Ulcerative colitis | 2.3 | 2.6 | -0.13 |
| Unhealthy Ageing | 1.9 | 1 | 0.9 |
| Vitiligo | 1.4 | 0.4 | 2.5 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
